Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 112 publications

Most recent new publication 1/2025

See all their publications

Vacancies in this group

Working in this group

Head of Biology and Director, Centre for Target Validation (Group Leader)

  • Sutton
  • Cancer Therapeutics
  • Competitive Starting Salary
  • Permanent

Under the leadership of Dr Olivia Rossanese, we are seeking to appoint a Team Leader to join The Centre for Cancer Drug Discovery (CCDD) as The Head of Biology and Director of the Centre for Target Validation. Key Requirements The successful candidate must have in-depth knowledge and recent experience in an area of cancer biology relevant to oncology drug discovery. Leadership experience of drug discovery within, or in collaboration with, the pharmaceutical or biotechnology industry as evidenced by publication and/or successful commercial projects. Along with completing the online application form, you will be asked to attach the following documents and failure to do so will mean your application cannot be considered on this occasion: · Full CV · Lists of major publications, achievements, research grants, distinctions. · A PDF of a maximum of five key publications, or other research outputs (e.g. patents) that best demonstrate previous productivity · You must also complete the personal statement section of the application form in the format of a covering letter including the names and contact details of three academic referees Department/Directorate Information: The Division of Cancer Therapeutic's mission is to develop personalised medicines by translating information from the cancer genome and cancer biology into drugs for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr Olivia Rossanese, Email [email protected]

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £38,700 - £45,500 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

14/02/25

Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos

Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body.

New research, published in Nature Communications, reveals how cancer cells are altered by their surroundings, enabling them to change their shape and break out of a tumour.  The discovery paves the way for treatments that will tackle cancer before it can spread.

Scaffolding around tumours acts as a 'roadmap'

Tumours are held together by a structure called the extracellular matrix (ECM), which acts like the scaffolding around a building under construction.

A team from The Institute of Cancer Research, London, and Barts Cancer Institute at Queen Mary University of London (BCI-QMUL), discovered how cancer cells use the layout of this scaffolding structure as a ‘roadmap’ to leave the tumour. They found that the ECM triggers changes within the cancer cells themselves – altering their shape and boosting their ability to travel to different parts of the body.

This breakthrough, which is the culmination of almost a decade of research that began at King’s College London, means that aggressive tumours that are likely to metastasise can now more easily be identified at an earlier stage – allowing clinicians to tailor treatment sooner. Drugs are currently in development to target the ECM’s layout, as well as the genes that drive these cell shape changes – which could stop cancer in its tracks before it can escape the tumour and spread.

Extracellular matrix provides the 'tracks' for cells to follow

The team, funded by Cancer Research UK and Barts Charity, and working in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research (ICR), looked at tumour tissue from 99 patients with melanoma skin cancer and breast cancer.

They saw that the ECM was laid out differently in three distinct areas of the tumour. Like scaffolding, the ECM is made up of a number of components, including pole-like fibres. At the centre of the tumour, the fibres were spread out and disorganised, whilst at the border they were tightly packed and thicker. At the outermost border of the tumour, the fibres were arranged pointing away from the tumour – providing the ‘tracks’ for the cancer cells to follow as they escape from the tumour. At this outermost border of the tumour, the cancer cells were rounded – a more invasive cell shape.

Aggressive cells have a different expression of genes

The team tested whether the conditions at the border of the tumour make the cancer cells more aggressive. They grew melanoma cancer cells in a model of these conditions and injected them into mice. Cancer cells grown in these conditions were more likely to spread to the lungs and metastasise than melanoma cells grown in control conditions with disorganised fibres.

The researchers saw differences in the type of genes present in the cells depending on where in the tumour they came from. Cells at the border of the tumour had more genes linked to cell migration, rounding of the cell shape, and inflammation – all making the cells more aggressive and likely to survive. The team also saw an increase in the expression of genes for enzymes that impact the organisation of the matrix – highlighting how cancer cells corrupt their surroundings to break out of the tumour.

Comparing these findings to cancers from patients with 14 different tumour types, including melanoma, breast, pancreatic, lung cancer and glioblastoma – an aggressive brain cancer – the researchers found that a higher presence of these genes was associated with a shorter survival time.

Treating cancer before it spreads

The researchers say that these findings open new avenues for treatment to tackle cancer before it can spread, such as drugs targeting lysyl oxidase (LOX), which are already in clinical trials for other conditions. These drugs work by targeting an enzyme that stabilises the matrix, which is found more abundantly in the border region of tumours. The ICR has previously carried out research to show the possibility of targeting LOX in cancer treatment.

Professor Victoria Sanz Moreno, Professor of Cancer Cell and Metastasis Biology at The Institute of Cancer Research, London, who led the study said:

“Our research has uncovered the roadmap that cancer cells follow to break out of a tumour, enabling it to cause a secondary tumour elsewhere in the body. Now that we understand this roadmap, we can look to target different aspects of it, to stop aggressive cancers from spreading.

“The fibres in the structure surrounding the tumour are denser and are laid out like a path for cells to follow, the further out at the border of the tumour that we look. Future research should explore ways to target this arrangement, to prevent cancer cells from being able to escape and follow this path. We may also find that targeting this dense arrangement of fibres means other drugs can reach cancer cells more easily, which could improve how well treatments work.” 

'What's on the outside of the tumour is just as important as what's in the centre'

Dr Oscar Maiques, Group Leader and Lecturer in Digital Pathology at the Barts Cancer Institute at Queen Mary University of London, said:

“This study is the culmination of almost a decade of research to understand how cancer cells interact with their surroundings, known as the extracellular matrix.

“Importantly, we see that various regions of the tumour hold different information about that cancer’s future behaviour. When clinicians biopsy the tumour, our research shows that what’s on the outside of the tumour is just as important as what’s in the centre – as this holds crucial information about whether a cancer is likely to spread.”

Cancer operates in a 'complex ecosystem'

Professor Kristian Helin, Chief Executive at The Institute of Cancer Research, London, said:

“We know that most cancer deaths occur because cancer has spread from the original tumour to other parts of the body, at which point it becomes much harder to treat. To develop better treatments for cancer patients, we must understand the complex ecosystem in which it operates. This research reveals how a tumour’s surroundings alter the cancer cells within it and enable them to spread. I hope that further research will lead to the development of treatments that target these interactions and prevent cancer from spreading.”

Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK, said:

“Understanding how cancer spreads is crucial to finding treatments which can stop the disease advancing further. This research shows how much cancer relies on the scaffolding around it to move and spread elsewhere. Cutting down this scaffolding could deprive cancer of opportunities to spread and improve the chances of successful treatment, and I look forward to further research which hopes to achieve this aim.”